GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Cyclically Adjusted PB Ratio

Qiagen NV (Qiagen NV) Cyclically Adjusted PB Ratio : 3.07 (As of May. 16, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV Cyclically Adjusted PB Ratio?

As of today (2024-05-16), Qiagen NV's current share price is $45.99. Qiagen NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $14.97. Qiagen NV's Cyclically Adjusted PB Ratio for today is 3.07.

The historical rank and industry rank for Qiagen NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

QGEN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.08   Med: 2.96   Max: 4.53
Current: 3.06

During the past years, Qiagen NV's highest Cyclically Adjusted PB Ratio was 4.53. The lowest was 2.08. And the median was 2.96.

QGEN's Cyclically Adjusted PB Ratio is ranked worse than
68.42% of 133 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.95 vs QGEN: 3.06

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Qiagen NV's adjusted book value per share data for the three months ended in Mar. 2024 was $16.226. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $14.97 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Qiagen NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Qiagen NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Cyclically Adjusted PB Ratio Chart

Qiagen NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.74 4.28 4.27 3.50 2.99

Qiagen NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.23 3.13 2.78 2.99 2.87

Competitive Comparison of Qiagen NV's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Qiagen NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Cyclically Adjusted PB Ratio falls into.



Qiagen NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Qiagen NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=45.99/14.97
=3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Qiagen NV's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=16.226/128.5800*128.5800
=16.226

Current CPI (Mar. 2024) = 128.5800.

Qiagen NV Quarterly Data

Book Value per Share CPI Adj_Book
201406 12.634 99.240 16.369
201409 12.411 99.960 15.964
201412 12.226 99.050 15.871
201503 11.367 99.750 14.652
201506 11.650 100.230 14.945
201509 11.578 100.500 14.813
201512 11.790 99.730 15.201
201603 12.039 100.310 15.432
201606 11.992 100.260 15.379
201609 12.183 100.570 15.576
201612 11.899 100.710 15.192
201703 11.003 101.440 13.947
201706 11.317 101.370 14.355
201709 11.688 102.030 14.729
201712 11.563 101.970 14.580
201803 11.703 102.470 14.685
201806 11.460 103.100 14.292
201809 11.516 103.950 14.245
201812 12.046 103.970 14.897
201903 11.837 105.370 14.444
201906 11.983 105.840 14.558
201909 11.231 106.700 13.534
201912 11.482 106.800 13.824
202003 11.258 106.850 13.548
202006 11.825 107.510 14.142
202009 12.219 107.880 14.564
202012 12.652 107.850 15.084
202103 12.863 108.870 15.192
202106 13.427 109.670 15.742
202109 13.667 110.790 15.862
202112 14.058 114.010 15.855
202203 14.686 119.460 15.807
202206 14.862 119.050 16.052
202209 15.067 126.890 15.268
202212 15.694 124.940 16.151
202303 16.100 124.720 16.598
202306 16.371 125.830 16.729
202309 16.688 127.160 16.874
202312 17.202 126.450 17.492
202403 16.226 128.580 16.226

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Qiagen NV  (NYSE:QGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Qiagen NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen NV (Qiagen NV) Business Description

Address
Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Executives
Prof. Dr. Elaine R. Mardis Supervisory Board
Roland Sackers Board of Directors
Thierry Bernard Board of Directors
Lawrence A. Rosen Supervisory Board